http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2770128-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7dc2b37eaa33659ea0e189613f0c184 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate | 2016-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b97b24c7ff8ee699eea2de3d208e94d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11cb4dce95da0c82cffde53858eb5799 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d146bf7c5a6b1f588394bc863bdc4479 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d159eb68d0c0bfedc00614a6fe5313e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_672ad4fbc70ed6628bbcb3c7f155ef58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_903149d2069fcf066cf6854bb6516c7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7200e206863453ebe0e9b1c3cec610a8 |
| publicationDate | 2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2770128-T3 |
| titleOfInvention | Useful condensed tricyclic pyrazole derivatives useful for modulating farnesoid x receptors |
| abstract | A compound according to Formula (II), ** (See formula) ** or a pharmaceutical acceptable salt thereof, where R0 is C1-6 alkyl; C1-6 haloalkyl; hydroxyC 1-6 alkyl; hydroxyC 1-6 alkyl substituted with halo; or phenyl optionally substituted with 1-2 substituents independently represented by R2; or R0 is selected from the group C3-7 cycloalkyl, a 5-10 membered heteroaryl comprising 1-3 N, O or S heteroatoms, and a 4-6 membered heterocycle comprising 1-2 N heteroatoms, O or S; wherein each of which is optionally substituted with 1-2 substituents represented by R2a; Ring B is aryl; 5-10 membered heteroaryl comprising 1-3 N, O or S heteroatoms; 4-6 membered heterocycle comprising 1-2 N, O or S heteroatoms; or C 3-7 cycloalkyl; wherein each of which is optionally substituted with 1-2 substituents independently represented by R2a; X is - (CR4R5) - or -C (O) -; L2 is * 2- (CR4R5) 1-2-; * 2- (CR4R5) -C (O) -; * 2- (CR4R5) -C (O) -NR-; * 2- (CR4R5) 2-O-; * 2- (CR4R5) 2-NR-; * 2- (CR4R5) 2-NR-SO2-; * 2- (CR4R5) 2-NR-C (O) -; * 2- (CR4R5) -C (O) -NR- (CR4R5) -; or * 2- (CR4R5) 2-NR-C (O) -NR- (CR4R5) 0-1; where "* 2" indicates the point of attachment of L2 to N; each R2 is independently halo, hydroxyl, C1-6 alkyl, halo-substituted C1-6 alkyl, -C (O) NR6R7; -S (O) 2-NR4N5; -C (O) O- (CR4CR5) 2-3NR4R5; -N (R) -C (O) O-R; -SO2R; -NR4R5 or - (CR4R5) -C (O) O; each R2a is independently halo, hydroxyl, C1-6 alkyl, C1-6 alkyl substituted with halo; each R3 is independently hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, or cyclopropyl; and R, R4, R5, R6 and R7 are independently hydrogen or C1-6 alkyl; alternatively R6 and R7 together with the N may form a 5-6 membered heterocyclic ring. |
| priorityDate | 2015-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 320.